Biotechnology company acquires license for Alzheimer’s disease vaccine
A company has acquired a DNA vaccine for Alzheimer’s disease that is designed to trigger an immune response to the disease. The vaccine, in preclinical development, differs from other Alzheimer’s vaccines under study in that it only contains a piece of the coding for the amyloid beta protein, a company statement said. Amyloid beta in […]